| 词条 | Cofetuzumab pelidotin |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = zu/o | target = protein tyrosine kinase 7 | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 1869937-48-3 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = 6774 | H = 10418 | N = 1778 | O = 2096 | S = 46 | molecular_weight = 151.7 g/mol | UNII = 249EAP69MT | KEGG = D11118 | synonyms = PF-06647020 | ChemSpiderID = none }} Cofetuzumab pelidotin (PF-06647020) (INN[1]) is a humanized monoclonal antibody designed for the treatment of cancer. This drug was developed by Pfizer Inc.[2] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 | journal = WHO Drug Information | volume = 31 | issue = 2 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for tumors}}2. ^[https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fcofetuzumab%2520pelidotin.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin], American Medical Association. 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。